Early in 2014 the ImmuVen, Inc. was acquired by AbbVie. The firm had been woring on development of drugs to treat viral diseases, autoimmune, staphylococcus aureus, bacterial diseases, infectious diseases, and cancer. The firmwas organzied around featuring a powerful,at-the-time emerging life science technology, T cell receptors, a unique class of immune-targeting therapeutic and diagnostic agents. These agents have significant advantages over antibodies, which are already a $20 billion/year market against cancer, autoimmune, and infectious diseases.ImmuVen had developed a suite of products that could detect and treat Staphylococcus aureus, including highly antibiotic resistant methicillin-resistant organisms (MRSA). It also developed products to treat Streptococcal disease. In addition, the company had been actively engaged in work on other T cell receptor-related drugs that are aimed at significant health problems associated with infectious viral diseases and cancer.
